You are here: Industry Insights > Market News > SII gets purchase order from government for 10 crore doses of Covishield

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

SII gets purchase order from government for 10 crore doses of Covishield

expresspharmaMarch 19, 2021

Tag: SII , Covishield , COVID-19 vaccine , AstraZeneca

Favorites

Serum Institute of India (SII) has received a new purchase order from the Government of India for the supply of 10-crore doses of the Oxford-AstraZeneca COVID-19 vaccine — Covishield — each dose costing Rs 157.5, including GST, according to official sources. HLL Lifecare, a PSU, has issued the supply order on behalf of the Union health ministry on March 12 in the name of Prakash Kumar Singh, Director, Government and Regulatory Affairs, at the Pune-based SII. The cost of the 10-crore doses would be borne by the health ministry.

Reportedly, the expenditure for the earlier orders of the COVID-19 vaccines was funded by PM Cares Fund, the sources added.

Previous:Maha wants to manufacture Covaxin at Haffkine: Rajesh Tope

Next:NPPA extends ceiling prices of Heparin Injection till Sept 2021

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

SII gets purchase order from government for 10 crore doses of Covishield | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

SII gets purchase order from government for 10 crore doses of Covishield

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

SII gets purchase order from government for 10 crore doses of Covishield

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>